The association between hyperhomocysteinemia and ischemic stroke in patients with non-valvular atrial fibrillation

Haematologica

Volumn 90, Issue 9, 2005, Pages 1205-1211

  Loffredo, Lorenzo ^a   Violi, Francesco ^a   Fimognari, Filippo Luca ^b   Cangemi, Roberto ^a   Sbrighi, Pier Sandro ^b   Sampietro, Francesca ^c   Mazzola, Giuseppina ^c   Di Lecce, Vito Nicola ^a   D'Angelo, Armando ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Ospedale Parodi Delfino   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Cardiovascular risk factors; Fibrinogen; Glomerular filtration rate; Homocysteine; Ischemic stroke; Non valvular atrial fibrillation

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FIBRINOGEN; HOMOCYSTEINE; PROPAFENONE; URIC ACID;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITALIZATION; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED;

EID: 25444436204     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hart RG. Atrial fibrillation and stroke prevention. N Engl J Med 2003;349:1015-6.
2. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978;28:973-7.
3. Conway DSG, Pearce LA, Chin BPS, Hart RG, Lip GYH. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation. 2003;107:3141-5.
4. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90:1-11.
5. de Koning ABL, Werstuck GH, Zhou J, Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem 2003;36:431-41.
6. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. JAMA 2002; 288:2015-22.
7. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 2002;325:1202-8.
8. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003;290:932-40.
9. Friedman HS. Serum homocysteine and stroke in atrial fibrillation. Ann Intern Med 2001;134:253-4.
10. Ay H, Arsava EM, Tokgozoglu SL, Ozer N, Saribas O. Hyperhomocysteinemia is associated with the presence of left atrial thrombus in stroke patients with nonvalvular atrial fibrillation. Stroke 2003;34:909-12.
11. Cingozbay BY, Yiginer O, Cebeci BS, Kardesoglu E, Demiralp E, Dincturk M. Role of homocysteine for thromboembolic complication in patients with non-valvular atrial fibrillation. Blood Coagul Fibrinol 2002;13:609-13.
12. Eikelboom JW, Hankey GJ, Anand SS, et al. Association between high homocysteine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke 2000;31:1069-75.
13. Marcucci R, Betti I, Cecchi E, Poli D, Giusti B, Fedi S, et al. Hyperhomocysteinemia and vitamin B6 deficiency: new risk markers for nonvalvular atrial fibrillation? Am Heart J 2004;148:456-61.
14. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004;50:3-32.
15. Joint National Committee. The Sixth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997;157:2413-44.
16. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-97.
17. Executive Summary of the Third Report of the National Cholesterol Education Program (NECP) Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
18. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957;17:237-40.
19. Fermo I, Arcelloni C, Mazzola G, D'Angelo A, Paroni R: High-performance liquid chromatographic method for measuring total plasma homocysteine levels. J Chromatogr B 1998;719:31-6.
20. Pengo V, Filippi B, Biasiolo A, Pegoraro C, Noventa F, Iliceto S. Association of the G20210A mutation in the factor II gene with systemic embolism in non-valvular atrial fibrillation. Am J Cardiol 2002;90:545-7.
21. D'Angelo A, Mazzola G, Fermo I. Gene-gene and gene-environment interactions in mild hyperhomocysteinemia. Pathophysiol Haemost Thromb 2004; 33:337-41.
22. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349:1019-26.
23. Di Lecce VN, Loffredo L, Fimognari FL, Cangemi R, Violi F. Fibrinogen as predictor of ischemic stroke in patients with non valvular atrial fibrillation. J Thromb Haemost 2003;1:2453-5.
24. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999;30:1223-9.
25. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999;131:688-95.
26. Pengo V, Legnani C, Noventa F, Palareti G, on behalf of the ISCOAT Study Group. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A multicenter inception cohort study. Thromb Haemost 2001;85:418-22.
27. Meade T, Zuhrie R, Cook C, Cooper J on behalf of the MRC General Practice Research Framework. Bezafibrate in men with lower extremity arterial disease: randomized controlled trial. Br Med J 2002;325:1139-43.
28. MacCallum PK, Cooper JA, Rumley A, Lowe GDO, Meade TW. Effect of bezafibrate on plasma homocysteine concentration in men with lower extremity arterial disease. J Thromb Haemost 2004;2:364-5.
29. th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, LB27, San Francisco CA, March 3-6, 2004.